ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near Montréal, QC, CAN:

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (SUGARNSALT)

Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors ...

Not yet enrolling
Kidney Failure, Chronic
Diabetic Nephropathies
Drug: Placebo
Drug: Sotagliflozin

Phase 3

Alessandro Doria

Montreal, Quebec, Canada and 18 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 338 other locations

compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...

Enrolling
Chronic Kidney Disease
Drug: Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
Drug: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg

Phase 2

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 116 other locations

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys...

Enrolling
Chronic Kidney Disease
Type 1 Diabetes Mellitus
Other: Placebo
Drug: Finerenone

Phase 3

Bayer
Bayer

Montreal, Quebec, Canada and 83 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Montreal, Canada and 290 other locations

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Placebo
Drug: Cagrilintide

Phase 2

Novo Nordisk
Novo Nordisk

Montreal, Quebec, Canada and 118 other locations

receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...

Active, not recruiting
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Finerenone Placebo

Phase 2

Bayer
Bayer

Montreal, Quebec, Canada and 188 other locations

Locations recently updated

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Montreal, Quebec, Canada and 191 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

Montreal, Quebec, Canada and 144 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)
Drug: Placebo

Phase 3

Bayer
Bayer

Montreal, Quebec, Canada and 129 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems